<DOC>
	<DOCNO>NCT00623480</DOCNO>
	<brief_summary>To evaluate effect secondary prophylaxis compare episodic treatment bleeding frequency ( number bleeds per year ) joint damage .</brief_summary>
	<brief_title>Trial Evaluate Effect Secondary Prophylaxis With rFVIII Therapy Severe Hemophilia A Adult and/or Adolescent Subjects Compared That Episodic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males age 12 50 year ( US Argentina ) Males age 18 50 year ( country ) Subjects severe hemophilia A ( &lt; 1 % FVIII : C ) confirm central lab sample obtain least 96 hour FVIII administration washout . Allow inclusion maximum 10 % ( n=8 ) patient 12 % FVIII : C baseline level long exhibit clinical severity comply inclusion criterion . Subjects least 150 prior exposure day FVIII Subjects episodic treatment know regular prophylaxis treatment 12 consecutive month previous 5 year Subjects 6 24 bleeding event and/or treatment previous 6 month prior study entry document available subject medical record . Documentation include record previous physician , specific home treatment record , emergency room hospital record , xray report , etc . The investigator also document detailed note number bleeds report subject last 6 month . Subjects inhibitor formation surveillance ( inhibitor recovery test ) ten year prior enrollment document investigator history following : A positive inhibitor titer 5.0 Bethesda Unit ( BU ) great either BU assay system time since first exposure exogenous factor VIII A positive inhibitor test result 1.0 great perform original BU assay time past 10 year ( A subject one positive inhibitor test 0.6 great original BU assay test must less 1.0 BU use original BU assay . ) A positive inhibitor test result 0.6 great perform Nijmegen method time past 10 year Subjects inhibitor activity Nijmegenmodified Bethesda assay , either positive ( &gt; 0.6 BU consider positive ) borderline ( &gt; 0.3 &lt; 0.6 BU consider borderline ) measure current study reference laboratory Subjects bleed disease besides hemophilia A ( i.e . von Willebrand disease ) Subjects thrombocytopenia ( platelet &lt; 100,000/mm3 ) Subjects abnormal renal function ( CockcroftGault Creatinine Clearance value 60 mL/min low ) Subjects active hepatic disease ( Aspartate aminotransferase [ AST ] Alanine aminotransferase [ ALT ] &gt; 5xUpper Limit Normal ( ULN ) ) Subjects treatment immunomodulatory agent within last 3 month prior study entry study ( follow drug however allow : interferona treatment Hepatitis C virus ( HCV ) , Highly active antiretroviral therapy ( HAART ) therapy human immunodeficiency virus ( HIV ) and/or total two course pulse treatment steroid maximum 7 day 1mg/kg less ) Subjects absolute CD4 lymphocyte cell count &lt; 200 cells/mm3 ( due HIV , HCV another suspect medical condition ) Subjects know hypersensitivity rFVIII , mouse hamster protein Subjects receive receive experimental drug within 1 month prior study entry Subjects require premedication tolerate FVIII injection ( e.g . antihistamine ) Subjects unwilling comply study visit either possible treatment regimen Subjects plan orthopedic intervention perform study may substantially affect bleeding ( e.g . surgical chemical radiological synovectomy ) Subjects suitable participation study reason , accord Investigator Subjects poor joint status define routine need wheelchair unable ambulate without assistance brace , cane crutch Three joint already fuse `` frozen '' also call ankylosis</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>